Abstracts tagged "hyperuricemia"

Abstract Number: 1125 • 2018 ACR/ARHP Annual Meeting
Association between Hyperuricemia and Metabolic Syndrome with or without Obesity: Results from the 2016 Korea National Health and Nutrition Examination Survey
In Young Kim¹, Yeong Hee Eun¹, Eun-Jung Park², Joong Kyong Ahn³, Chan Hong Jeon⁴, Jaejoon Lee⁵, Hoon-Suk Cha¹, Eun-Mi Koh⁵, Kyungdo Han⁶ and Hyungjin Kim¹, ¹Department of Medicine, Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Division of Rheumatology, National Medical Center, Seoul, Korea, Republic of (South), ³Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Division of Rheumatology, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine,Division of Rheumatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ⁶Department of Biostatistics, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Hyperuricemia is increasing worldwide, and is emerging as a potential biomarker and predictor for metabolic syndrome and related complications. We aimed this study to…
Abstract Number: 1270 • 2018 ACR/ARHP Annual Meeting
Lack of Association of Comorbidities with Ultrasonographic Urate Deposition in Asymptomatic Hyperuricemia
Sharon Dowell¹, Gail S. Kerr², Alvin F. Wells³, Richard Haddad⁴, Paul DeMarco⁵, Joyce Joseph⁶, Mercedes Quinones⁷, Shelby Hochberg⁸, Jennifer Ude⁹, Jim Huang¹⁰ and David Nashel⁶, ¹Division of Rheumatology, Howard University, Washington, DC, ²Rheumatology, Washington DC VAMC and Georgetown and Howard University, Washington, DC, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴The Hospital for Special Surgery, New York, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center, Washington, DC, ⁷Internal Medicine, Division of Rheumatology, Washington DC VA Medical Center and Howard University, Washington, DC, ⁸Washington DC VA Medical Center and Howard University, Washinton, DC, ⁹Washington DC VA Medical Center and Howard University, Washington, DC, ¹⁰Medstar Health Research Institute, Hyattsville, MD
Background/Purpose: Hyperuricemia is common, and along with other comorbidities (CM), is increasing in prevalence. Though often asymptomatic, it is associated with subclinical urate deposition detectable…
Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Danica Grujic¹, Aditi Desphande¹, Robert Terkeltaub², Nadia Mosiichuk³, Kateryna Goncharva⁴ and Stefan Pirzynowski⁴, ¹R&D, Allena Pharmaceuticals, Newton, MA, ²VA San Diego Healthcare System, San Diego, CA, ³SGPlus and Lund University, Lund, Sweden, ⁴Lund University and SGPlus, Lund, Sweden
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…
Abstract Number: 2219 • 2018 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics and Pharmacodynamics of NC-2500, a Novel Xanthine Oxidoreductase Inhibitor, in Healthy Volunteers
Masuharu Hirano¹, Shiro Kobayashi², Eri Miyayama², Takashi Ohta¹, Masao Yamamoto² and Tomio Yamakawa³, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Development Planning Department, Nippon Chemiphar Co., Ltd., Chiyoda-ku, Tokyo, Japan, ³Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: Gout flare due to rapid urate reduction after initiating urate-lowering therapy (ULT) is one of the major issues in the therapy. International guidelines recommend…
Abstract Number: 2246 • 2018 ACR/ARHP Annual Meeting
Insulin: Genetic and Physiological Influences on Human Uric Acid Homeostasis
David B. Mount¹, Tony R. Merriman² and Asim Mandal¹, ¹Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²University of Otago, Dunedin, New Zealand
Background/Purpose: Insulin plays a key role in the genesis of hyperuricemia. In particular, hyperinsulinemia in metabolic syndrome is inversely correlated with urinary uric acid (UA)…
Abstract Number: 2967 • 2018 ACR/ARHP Annual Meeting
Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Laura Gabriela Sánchez Lozada¹, Fernando E. García-Arroyo², J. Gabriel Juárez-Rojas³, Guillermo Gonzaga² and Raymond P. Warrell Jr.⁴, ¹Nephrology, INC Ignacio Chavez, Mexico City, Mexico, ²INC Ignacio Chavez, Mexico City, Mexico, ³INC Ignacio Chavez, Mexoci City, Mexico, ⁴Relburn-Metabolomics, Inc., Westfield, NJ
Background/Purpose: Dietary fructose promotes an increase in uric acid (UA) that may lead to gout. UA itself promotes lipogenesis and inflammation in both gout as…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 2081 • 2017 ACR/ARHP Annual Meeting
Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia
Mariano Andrés^1,2, José Antonio Bernal³, María Dolores Arenas⁴ and Eliseo Pascual^1,5, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ⁴Unidad de Nefrología, Hospital Vithas Perpetuo Socorro, Alicante, Spain, ⁵Emeritus Professor, Universidad Miguel Hernández, Elche, Spain
Background/Purpose: Articular and periarticular deposits of monosodium urate (MSU) crystals in asymptomatic hyperuricemia (AH) may associate with more severe forms of atherosclerosis [Andrés 2016]. This…
Abstract Number: 170 • 2017 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Ascertained Gout and Subtypes Identifies Multiple Susceptibility Loci Including Transporter Genes
Hirotaka Matsuo¹, Akiyoshi Nakayama², Hirofumi Nakaoka³, Ken Yamamoto⁴, Masayuki Sakiyama⁵, Amara Shaukat⁶, Yu Toyoda⁷, Yukinori Okada⁸, Yoichiro Kamatani⁹, Masahiro Nakatochi¹⁰, Takahiro Nakamura⁵, Tappei Takada⁷, Hiroshi Nakashima⁵, Seiko Shimizu⁵, Makoto Kawaguchi⁵, Asahi Hishida¹¹, Kenji Wakai¹¹, Blanka Stiburkova¹², Karel Pavelka¹³, Lisa K. Stamp¹⁴, Nicola Dalbeth¹⁵, Tatsuo Hosoya¹⁶, Michiaki Kubo⁹, Hiroshi Ooyama¹⁷, Toru Shimizu¹⁸, Kimiyoshi Ichida¹⁹, Tony R. Merriman²⁰ and Nariyoshi Shinomiya²¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Dept Integrative Physiol, National Defense Med College, Tokorozawa, Japan, ³National Inst Genet, Mishima, Japan, ⁴Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ⁵National Defense Med College, Tokorozawa, Japan, ⁶Univ Otago, Dunedin, New Zealand, ⁷Univ Tokyo Hosp, Tokyo, Japan, ⁸Osaka University, Osaka, Japan, ⁹Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ¹⁰Nagoya Univ Hosp, Nagoya, Japan, ¹¹Nagoya Univ Grad Sch Med, Nagoya, Japan, ¹²Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Rheumatology, Prague, Czech Republic, ¹⁴University of Otago, Christchurch, New Zealand, ¹⁵University of Auckland, Auckland, New Zealand, ¹⁶Jikei Univ Sch Med, Tokyo, Japan, ¹⁷Ryougoku East Gate Clin, Tokyo, Japan, ¹⁸Kyoto Industr Health Assoc, Kyoto, Japan, ¹⁹Tokyo Univ Pharmacy Life Sci, Tokyo, Japan, ²⁰Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²¹National Defense Med College, Saitama, Japan
Background/Purpose: We performed a genome-wide association study (GWAS) of gout and its subtypes to identify novel gout loci including those that are subtype-specific. Methods: Putative…
Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Doo-Ho Lim¹, Seokchan Hong², Ji Seon Oh³, Yong-Gil Kim², Chang Keun Lee², Seung Won Choi¹ and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…
Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Michael Gillen¹, Zangong Shen² and Jeffrey N. Miner³, ¹AstraZeneca, Gaithersburg, MD, ²Ardea Biosciences, San Diego, CA, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…
Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
James VanderLugt¹, Michael Gillen², Xiaojuan Yang³ and Jesse Hall³, ¹Jasper Clinical Research & Development, Kalamazoo, MI, ²AstraZeneca, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
William B Smith¹, Jesse Hall², Jolene Berg³, Michal Kazimir⁴, Amy Yamamoto², Caroline Lee², Susan Walker² and Thomas C. Marbury⁵, ¹Volunteer Research Group, Knoxville, TN, ²Ardea Biosciences, Inc., San Diego, CA, ³DaVita Clinical Research, Minneapolis, MN, ⁴DaVita Clinical Research, Lakewood, CO, ⁵Orlando Clinical Research Center, Orlando, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…
Abstract Number: 193 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Michael Gillen¹, Jeffrey N. Miner² and Shakti Valdez³, ¹AstraZeneca, Gaithersburg, MD, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, single-blind, placebo-controlled study (. Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive…